Vis enkel innførsel

dc.contributor.authorBöhm, Maria-Elisabeth
dc.contributor.authorRazavi, Mohammad
dc.contributor.authorMarathe, Nachiket
dc.contributor.authorFlach, Carl-Fredrik
dc.contributor.authorLarsson, D. G. Joakim
dc.date.accessioned2021-02-16T11:42:46Z
dc.date.available2021-02-16T11:42:46Z
dc.date.created2021-01-14T15:35:57Z
dc.date.issued2020
dc.identifier.citationMicrobiome. 2020, 8 (1), 1-11.en_US
dc.identifier.issn2049-2618
dc.identifier.urihttps://hdl.handle.net/11250/2728355
dc.description.abstractBackground New antibiotic resistance determinants are generally discovered too late, long after they have irreversibly emerged in pathogens and spread widely. Early discovery of resistance genes, before or soon after their transfer to pathogens could allow more effective measures to monitor and reduce spread, and facilitate genetics-based diagnostics. Results We modified a functional metagenomics approach followed by in silico filtering of known resistance genes to discover novel, mobilised resistance genes in class 1 integrons in wastewater-impacted environments. We identified an integron-borne gene cassette encoding a protein that conveys high-level resistance against aminoglycosides with a garosamine moiety when expressed in E. coli. The gene is named gar (garosamine-specific aminoglycoside resistance) after its specificity. It contains none of the functional domains of known aminoglycoside modifying enzymes, but bears characteristics of a kinase. By searching public databases, we found that the gene occurs in three sequenced, multi-resistant clinical isolates (two Pseudomonas aeruginosa and one Luteimonas sp.) from Italy and China, respectively, as well as in two food-borne Salmonella enterica isolates from the USA. In all cases, gar has escaped discovery until now. Conclusion To the best of our knowledge, this is the first time a novel resistance gene, present in clinical isolates, has been discovered by exploring the environmental microbiome. The gar gene has spread horizontally to different species on at least three continents, further limiting treatment options for bacterial infections. Its specificity to garosamine-containing aminoglycosides may reduce the usefulness of the newest semisynthetic aminoglycoside plazomicin, which is designed to avoid common aminoglycoside resistance mechanisms. Since the gene appears to be not yet common in the clinics, the data presented here enables early surveillance and maybe even mitigation of its spread.en_US
dc.language.isoengen_US
dc.titleDiscovery of a novel integron-borne aminoglycoside resistance gene present in clinical pathogens by screening environmental bacterial communitiesen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.source.pagenumber1-11en_US
dc.source.volume8en_US
dc.source.journalMicrobiomeen_US
dc.source.issue1en_US
dc.identifier.doi10.1186/s40168-020-00814-z
dc.identifier.cristin1871499
dc.source.articlenumber41en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel